CVCamiel Verhamme

Camiel Verhamme

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Camiel Verhamme has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Luuk Wieske

    Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC University of Amsterdam Amsterdam the Netherlands

    4 shared publications
  • Roy Beekman

    Department of Neurology, Zuyderland Medical Center, Heerlen, Netherlands

    4 shared publications
  • Filip Eftimov

    Department of Neurology and Clinical Neurophysiology, Amsterdam UMC location University of Amsterdam, the Netherlands

    3 shared publications
  • Filip Eftimov

    Department of Neurology Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands

    3 shared publications
  • Ivo N. van Schaik

    Department of Neurology Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience Amsterdam the Netherlands

    3 shared publications
  • Marianne de Visser

    Department of Neurology, Amsterdam Neuroscience Amsterdam University Medical Centre, Location Academic Medical Centre, University of Amsterdam Amsterdam the Netherlands

    3 shared publications

Latest Publications

  • Open Access

    The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    by Iris N. van Doorn, Adája E. Baars, Luuk Wieske, Bart C. Jacobs, Krista Kuitwaard, W. Ludo van der Pol, Pieter A. van Doorn, Ivo N. van Schaik, Filip Eftimov, H. Stephan Goedee, et al.

    Background: Diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP) relies on clinical and electrodiagnostic features. In 2021, the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) revised the CIDP guideline, superseding the 2010 European Federation of Neurological Societies (EFNS)/PNS guideline. This study compares the diagnostic accuracy of both guidelines and evaluates the impact of specific criterion changes and nerve conduction study (NCS) extensiveness. Methods: Patients with CIDP were included if they fulfilled the 2010 EFNS/PNS electrodiagnostic criteria for at least possible CIDP or had a presumptive clinical CIDP diagnosis with objective treatment response. Matched controls were patients with suspected chronic immune‐mediated neuropathy who received a diagnosis other than CIDP. Diagnostic accuracy was evaluated using two thresholds: one including possible CIDP and one restricted to (probable/definite) CIDP. The impact of electrodiagnostic criteria changes and NCS extensiveness on diagnostic performance was assessed. Results: We included 339 patients and 339 matched controls. Sensitivity of the 2010 EFNS/PNS guideline was 92% when including possible CIDP and 91% for probable/definite CIDP, with specificities of 67% and 78%, respectively. For the 2021 EAN/PNS guideline, sensitivity was 94% when including possible CIDP and 83% for CIDP, with specificities of 66% and 86%, respectively. Differences were due to sensory criteria and changes in conduction block criteria. Unilateral NCS would miss 77 possible CIDP diagnoses. Conclusion: Sensitivity and specificity were comparable when including possible CIDP, but the 2021 EAN/PNS guideline showed lower sensitivity and higher specificity for CIDP alone. Modifying criteria, including removal of sensory abnormalities, and more extensive NCS enhanced accuracy.

  • DISTRICTS trial: enhancing carpal tunnel syndrome treatment – Authors' reply

    by Camiel Verhamme, Wijnand A C Palmbergen, A Marijne Heeren, Roy Beekman, Rob M A de Bie

  • Open Access

    Search for Additional Pathogenic Variants to Explain Variation in PMP22 -Related Neuropathies

    by Barbara W. van Paassen, Camiel Verhamme, Fred van Ruissen, Martin A. Haagmans, Marcel G.W. Dijkgraaf, Marianne De Visser, Frank Baas, Anneke J. Van Der Kooi, Marian A.J. Weterman

    The aim of this study was to investigate whether the considerable phenotypic variation in Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP) is due to additional pathogenic coding variants in severely affected patients, by screening a panel of neuropathy-related genes. In this cross-sectional study, the extremes of the spectrum of 742 patients with genetically confirmed CMT1A and HNPP were selected, based on disability as assessed using the Overall Neuropathy Limitation Scale (ONLS). The ONLS data of 183 patients with CMT1A and 102 with HNPP showed a Gaussian distribution. A next-generation sequencing panel containing 177 neuropathy-related genes was tested in a selected group of 20 patients with mild CMT1A, 24 with severe CMT1A, 25 with mild HNPP, and 25 with severe HNPP. One additional autosomal dominant pathogenic variant in the MFN2 gene was identified in a severe CMT1A case. Heterozygous pathogenic variants in autosomal recessive neuropathy–related genes were found in 2 patients with severe CMT1A and in 2 with mild HNPP. In our study, additional pathogenic coding variants in neuropathy-related genes did not contribute to variation in disease severity in most patients with CMT1A and HNPP. In cases with confirmed PMP22 copy-number alterations, further genetic screening for pathogenic variants in CMT-related genes is warranted only in severe cases.

  • Open Access

    Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases

    by Sander Oorschot, Merel-Anne Brehm, Annerieke C. van Groenestijn, Tim Veneman, Jos Twisk, Camiel Verhamme, Filip Eftimov, Judith G.M. Jelsma, Vibeke Valkenburg, Esther Kruitwagen, et al.

    The quality of evidence for improving physical fitness in people with neuromuscular diseases (NMDs) through aerobic exercise is low. The aim of this study was to evaluate the efficacy of combined personalized home-based aerobic exercise and coaching on physical fitness in people with NMD, compared with usual care. In a multicenter, assessor-blinded, randomized controlled trial, participants with different types of NMD were randomized (1:1 ratio) to a 6-month intervention (personalized home-based aerobic exercise and coaching) or usual care. Assessments were performed at baseline, directly after intervention, and at 6 and 12 months after intervention. The primary outcome was physical fitness, measured as peak oxygen uptake (VO2peak) directly after intervention. Secondary outcomes included daily physical activity, quality of life, physical functioning, metabolic syndrome markers, and creatine kinase level. We conducted intention-to-treat linear mixed-model analyses for all outcomes, with the baseline value of the particular outcome as covariate. Ninety-one participants (median age = 64.0, 60% female) were randomized to the intervention (n = 44) or usual care (n = 47) group. The mean group difference in VO2peak directly after intervention was 2.2 mL/min/kg (95% CI 0.2–4.1, p = 0.028) and 1.7 mL/min/kg (95% CI 0.1–3.4, p = 0.039) on average over time, in favor of the intervention group. There were no significant between-group differences in the secondary outcomes. Twenty-five and 22 adverse events were reported in the intervention and usual care groups, respectively. Creatine kinase levels remained unchanged. This study provides evidence that combined personalized home-based aerobic exercise and coaching is safe and improves physical fitness in people with NMD, but without evidence of improved physical functioning, daily physical activity, quality of life, or metabolic syndrome markers. This home-based approach has good potential for wider implementation. Future research should explore the association between changes in VO2peak and functional outcomes and strategies to counteract the slightly diminishing long-term intervention effect. The study was registered in the Netherlands Trial Register (ID: NL7344) on November 5, 2018. The first participant enrolled on September 19, 2018. However, the Ethics Review Committee of the Amsterdam Medical Center approved the study protocol on November 7, 2017. No adjustments were made to the approved study protocol, and the register corresponds one on one with the approved study protocol. This study provides Class II evidence that a 6-month personalized aerobic exercise program combined with coaching improves maximal aerobic capacity in patients with NMDs without effective cures.


  • Surgery versus corticosteroid injection for carpal tunnel syndrome (DISTRICTS): an open-label, multicentre, randomised controlled trial

    by Wijnand A C Palmbergen, Roy Beekman, A Marijne Heeren, Bart F L van Nuenen, Tim W H Alleman, Esther Verstraete, Korné Jellema, Wim I M Verhagen, Leo H Visser, Godard C W de Ruiter, et al.


  • Open Access

    Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives

    by Iris N van Doorn, Filip Eftimov, Luuk Wieske, Ivo N van Schaik, Camiel Verhamme

    Diagnosing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) poses numerous challenges. The heterogeneous presentations of CIDP variants, its mimics, and the complexity of interpreting electrodiagnostic criteria are just a few of the many reasons for misdiagnoses. Early recognition and treatment are important to reduce the risk of irreversible axonal damage, which may lead to permanent disability. The diagnosis of CIDP is based on a combination of clinical symptoms, nerve conduction study findings that indicate demyelination, and other supportive criteria. In 2021, the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) published a revision on the most widely adopted guideline on the diagnosis and treatment of CIDP. This updated guideline now includes clinical and electrodiagnostic criteria for CIDP variants (previously termed atypical CIDP), updated supportive criteria, and sensory criteria as an integral part of the electrodiagnostic criteria. Due to its many rules and exceptions, this guideline is complex and misinterpretation of nerve conduction study findings remain common. CIDP is treatable with intravenous immunoglobulins, corticosteroids, and plasma exchange. The choice of therapy should be tailored to the individual patient’s situation, taking into account the severity of symptoms, potential side effects, patient autonomy, and past treatments. Treatment responses should be evaluated as objectively as possible using disability and impairment scales. Applying these outcome measures consistently in clinical practice aids in recognizing the effectiveness (or lack thereof) of a treatment and facilitates timely consideration of alternative diagnoses or treatments. This review provides an overview of the current perspectives on the diagnostic process and first-line treatments for managing the disease.


  • Open Access

    Artificial intelligence-based classification of motor unit action potentials in real-world needle EMG recordings

    by Deborah Hubers, Wouter Potters, Olivier Paalvast, Sterre de Jonge, Brian Doelkahar, Martijn Tannemaat, Luuk Wieske, Camiel Verhamme


  • Open Access

    The effect of tremor on disability assessment in chronic inflammatory demyelinating polyradiculoneuropathy

    by R. van Veen, G. Pallada, L. Wieske, S. E. M. Ten Holter, A. F. van Rootselaar, C. Verhamme, R. M. A. de Bie, I. N. van Schaik, I. S. J. Merkies, J. M. Dijk, et al.

    Tremor in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is common, often unresponsive to treatment, and may contribute to disability. We aim to investigate whether tremor is associated with disability as measured in daily practice and clinical trials, independent of other impairments. We included 76 CIDP patients in this cross-sectional study. We assessed tremor with the Tremor Research Group essential tremor rating assessment scale (TETRAS) and the Fahn-Tolosa-Marin clinical rating scale (FTM). Disability was measured with the inflammatory Rasch-built overall disability scale (I-RODS) and the adjusted Inflammatory Neuropathy Cause and Treatment disability scale (INCAT-DS, categorized separately in arm score, or total score). Impairments including strength, sensory impairment, and fatigue were measured using specific impairment scales. We tested whether "the presence of a clinically relevant tremor" (based on TETRAS and FTM) or "tremor severity" (FTM part B sum score) was associated with disability scores (I-RODS, INCAT-DS total score, and INCAT-DS arm score), independent of the impairment scores, using multivariate regression. Both "the presence of a clinically relevant tremor" and "tremor severity" were significantly associated with disability measured by the INCAT-DS (arm score and total score), but not the I-RODS, independent of strength, sensory impairment, and fatigue. The explained variances were low. Clinically relevant tremor can (partly) explain disability in CIDP, as measured with the INCAT-DS, independent of muscle strength, sensory deficits, and fatigue. To assess disease activity in CIDP patients with tremor, both impairment and disability outcomes should be assessed, as disability is caused partly by tremor while the effect of immunotherapy on tremor seems limited.


  • Open Access

    Dutch injection versus surgery trial in patients with carpal tunnel syndrome (DISTRICTS): protocol of a randomised controlled trial comparing two treatment strategies

    by Wijnand A C Palmbergen, Rob M A de Bie, Tim W H Alleman, Esther Verstraete, Korne Jellema, Wim I M Verhagen, Geert J F Brekelmans, Godard C W de Ruiter, Diederik van de Beek, Corianne A J M de Borgie, et al.

    Introduction Carpal tunnel syndrome (CTS) is the most common peripheral neuropathy. The optimal treatment strategy is still unknown. The objective of the Dutch Injection versus Surgery TRIal in patients with CTS (DISTRICTS) is to investigate if initial surgery of CTS results in a better clinical outcome and is more cost-effective when compared with initial treatment with corticosteroid injection. Methods and analysis The DISTRICTS is an ongoing multicenter, open-label randomised controlled trial. Participants with CTS are randomised to treatment with surgery or with a corticosteroid injection. If needed, any additional treatments after this first treatment are allowed and these are not dictated by the study protocol. The primary outcome is the difference between the groups in the proportion of participants recovered at 18 months. Recovery is defined as having no or mild symptoms as measured with the 6-item carpal tunnel symptoms scale. Secondary outcome measurements are among others: time to recovery, hand function, patient satisfaction, quality of life, additional treatments, adverse events, and use of care and health-related costs. Ethics and dissemination The study was approved by the Medical Ethical Committee of the Amsterdam University Medical Centers (study number 2017-171). Study results will be disseminated in peer-reviewed journals and conferences. Trial registration number ISRCTN Registry: 13164336.